open access

Vol 14, No 4 (2018)
Guidelines / Expert consensus
Published online: 2018-04-23
Get Citation

Nutritional treatment

Stanisław Kłęk1, Aleksandra Kapała2
DOI: 10.5603/OCP.2018.0028
Oncol Clin Pract 2018;14(4):216-225.


  1. Department of General Surgery, Oncology, and Treatment of Digestive System Disorders, Multispecialty Stanley Dudrick Memorial Hospital in Skawina
  2. Maria Sklodowska-Curie Institute — Oncology Centre in Warsaw

open access

Vol 14, No 4 (2018)
Published online: 2018-04-23


Not available


Not available
Get Citation
About this article

Nutritional treatment


Oncology in Clinical Practice


Vol 14, No 4 (2018)

Article type

Guidelines / Expert consensus



Published online




Bibliographic record

Oncol Clin Pract 2018;14(4):216-225.


Stanisław Kłęk
Aleksandra Kapała

References (24)
  1. Sobotka L. Podstawy żywienia klinicznego. Krakowskie Wydawnictwo Scientifica, Kraków 2014.
  2. Krzemieniecki K. Leczenie wyniszczenia nowotworowego – dobrodziejstwo dla chorych a przekleństwo dla NFZ?Krytyczna analiza zjawiska terapii wyniszczenia nowotworowego w Polsce;. Współczesna Onkologia. 2008; 12(1): 38–42.
  3. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011; 12(5): 489–495.
  4. Góraj E. Ocena stadium zaawansowania wyniszczenia nowotworowego w momencie rozpoznania oraz jakościowa i ilościowa analiza zastosowanego leczenia wyniszczenia u chorych leczonych onkologicznie, Raport podsumowujący. (2014).
  5. Grabiec K, Burchert M, Milewska M, et al. Systemic and local mechanisms leading to cachexia in cancer. Postępy Higieny i Medycyny Doświadczalnej. 2013; 67: 1397–1409.
  6. Andreyev HJ, Norman AR, Oates J, et al. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer. 1998; 34(4): 503–509.
  7. Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 1980; 69(4): 491–497.
  8. Berclaz G. Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Annals of Oncology. 2004; 15(6): 875–884.
  9. Manilich E, Vogel JD, Kiran RP, et al. Key factors associated with postoperative complications in patients undergoing colorectal surgery. Dis Colon Rectum. 2013; 56(1): 64–71.
  10. Arrieta O, Michel Ortega RM, Villanueva-Rodríguez G, et al. Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study. BMC Cancer. 2010; 10: 50.
  11. Hofman M, Ryan JL, Figueroa-Moseley CD, et al. Cancer-Related Fatigue: The Scale of the Problem. The Oncologist. 2007; 12(suppl_1): 4–10.
  12. von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle. 2010; 1(1): 1–5.
  13. Nipp RD, Greer JA, El-Jawahri A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010; 363(8): 733–742.
  14. Aapro M, Arends J, Bozzetti F, et al. ESMO (European School of Medical Oncology). Early recognition of malnutrition and cachexia in the cancer patient: a position paper of a European School of Oncology Task Force. Ann Oncol. 2014; 25(8): 1492–1499.
  15. Maddocks M, Murton AJ, Wilcock A. Therapeutic exercise in cancer cachexia. Crit Rev Oncog. 2012; 17(3): 285–292.
  16. Ries A, Trottenberg P, Elsner F, et al. A systematic review on the role of fish oil for the treatment of cachexia in advanced cancer: an EPCRC cachexia guidelines project. Palliat Med. 2012; 26(4): 294–304.
  17. Solheim TS, Fearon KCH, Blum D, et al. Non-steroidal anti-inflammatory treatment in cancer cachexia: a systematic literature review. Acta Oncol. 2013; 52(1): 6–17.
  18. Isenring EA, Capra S, Bauer JD, et al. The impact of nutrition support on body composition in cancer outpatients receiving radiotherapy. Acta Diabetol. 2003; 40 Suppl 1(3): S162–S164.
  19. Mantovani G, Macció A, Bianchi A, et al. Megestrol acetate in neoplastic anorexia/cachexia: clinical evaluation and comparison with cytokine levels in patients with head and neck carcinoma treated with neoadjuvant chemotherapy. International Journal of Clinical and Laboratory Research. 1995; 25(3): 135–141.
  20. McQuellon R, Moose D, Russell G, et al. Supportive use of megestrol acetate (Megace) with head/neck and lung cancer patients receiving radiation therapy. International Journal of Radiation Oncology*Biology*Physics. 2002; 52(5): 1180–1185.
  21. Lundholm K, Gelin J, Hyltander A, et al. Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res. 1994; 54(21): 5602–5606.
  22. McMillan DC, Wigmore SJ, Fearon KC, et al. A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. Br J Cancer. 1999; 79(3-4): 495–500.
  23. Zang J, Hou M, Gou HF, et al. Antiemetic activity of megestrol acetate in patients receiving chemotherapy. Support Care Cancer. 2011; 19(5): 667–673.
  24. Zhan P, Wang Q, Qian Q, et al. Megestrol acetate in cancer patients with anorexia-cachexia syndrome: a meta-analysis. Transl Cancer Res. 2013; 2(2): 74–79.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: